Exact Mass: 466.3294
Exact Mass Matches: 466.3294
Found 98 metabolites which its exact mass value is equals to given mass value 466.3294,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
N-Linoleoyl Tryptophan
N-linoleoyl tryptophan belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Linoleic acid amide of Tryptophan. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Linoleoyl Tryptophan is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Linoleoyl Tryptophan is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
Cholesterol phosphate
28-Norbrassinolide
28-norbrassinolide belongs to brassinolides and derivatives class of compounds. Those are cholestane based steroid lactones containing benzo[c]indeno[5,4-e]oxepin-3-one. 28-norbrassinolide is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). 28-norbrassinolide can be found in tea and turnip, which makes 28-norbrassinolide a potential biomarker for the consumption of these food products.
(3alpha,5beta,7alpha,12alpha)-form-3,7,12,27-Tetrahydroxycholesten-26-oic acid
(24S)-3beta,4beta,6alpha,8,24-pentahydroxy-5alpha-cholestan-15-one|certonardosterol Q2
(3beta, 5alpha, 6alpha, 24E)-Cholest-24-ene-3, 6, 8, 14, 15, 26-hexol, 9CI
O-3-(beta-methyl)valeroyl alpha-bisabolol beta-D-fucopyranoside
(23R,24S)-3beta,11alpha,16beta,23,24-pentahydroxy-5alpha-cholestan-6-one
2-(3-eicosadienoyloxy-2-hydroxypropanoxy)methylpropenoic acid
(2alpha, 3beta, 5alpha, 6beta, 9alpha, 11alpha)-Cholest-7-ene-2, 3, 5, 6, 9, 11-hexol
2beta,3beta,14,20,22,25-hexahydroxy-5-cholest-7-ene
(22E,24R)-5alpha-cholest-22-ene-3beta,4beta,6alpha,8,15beta,24-hexaol
(6R)-2-(hydroxymethyl)-6-((3R,5R,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)heptanoic acid
(6R)-3-hydroxy-2-methyl-6-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)heptanoic acid
(6R)-2-methyl-6-((2R,3S,5S,7R,8R,9S,10S,12S,13R,14S,17R)-2,3,7,12-tetrahydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)heptanoic acid
(2S,3R,6R)-3-hydroxy-2-methyl-6-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)heptanoic acid
(2R,3R,6R)-3-hydroxy-2-methyl-6-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)heptanoic acid
(2S,3S,6R)-3-hydroxy-2-methyl-6-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)heptanoic acid
(2R,3S,6R)-3-hydroxy-2-methyl-6-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)heptanoic acid
24,24-difluoro-1α,25-dihydroxy-24a-homovitamin D3 / 24,24-difluoro-1α,25-dihydroxy-24a-homocholecalciferol
2β,3α,7α,12α-Tetrahydroxy-5β-cholestan-26-oic acid
3α,7α,12α,22-Tetrahydroxy-5β-cholestan-26-oic acid
3α,7α,12α,24-Tetrahydroxy-5α-cholestan-26-oic acid
3α,7α,12α,23-Tetrahydroxy-5β-cholestan-26-oic acid
1β,3α,7α,12α-Tetrahydroxy-5β-cholestan-26-oic acid
3α,6α,7α,12α-Tetrahydroxy-5β-cholestan-26-oic acid
3α,7α,12α,25-Tetrahydroxy-5β-cholestan-26-oic acid
2beta,3alpha,7alpha,12alpha-Tetrahydroxy-5beta-cholestan-26-oic acid
3alpha,7alpha,12alpha,22-Tetrahydroxy-5beta-cholestan-26-oic acid
3alpha,7alpha,12alpha,24-Tetrahydroxy-5alpha-cholestan-26-oic acid
3alpha,7alpha,12alpha,23-Tetrahydroxy-5beta-cholestan-26-oic acid
1beta,3alpha,7alpha,12alpha-Tetrahydroxy-5beta-cholestan-26-oic acid
3alpha,6alpha,7alpha,12alpha-Tetrahydroxy-5beta-cholestan-26-oic acid
3alpha,7alpha,12alpha,25-Tetrahydroxy-5beta-cholestan-26-oic acid
3alpha,7alpha,22S-trihydroxy-5alpha-cholestan-26-oic acid
3alpha,7alpha,12alpha,26-tetrahydroxy-5alpha-cholestan-27-oic acid
(25R)-1beta,3alpha,7alpha,12alpha-tetrahydroxy-5beta-cholestan-26-oic acid
(25S)-2beta,3alpha,7alpha,12alpha-tetrahydroxy-5beta-cholestan-26-oic acid
3alpha,7alpha,12alpha,22S-tetrahydroxy-5beta-cholestan-26-oic acid
(25S)-3alpha,7alpha,12alpha,24R-tetrahydroxy-5beta-cholestan-26-oic acid
(25R)-3alpha,7alpha,12alpha,24R-tetrahydroxy-5beta-cholestan-26-oic acid
(25S)-3alpha,7alpha,12alpha,24S-tetrahydroxy-5beta-cholestan-26-oic acid
(25R)-3alpha,7alpha,12alpha,24S-tetrahydroxy-5beta-cholestan-26-oic acid
3alpha,7alpha,12alpha,26-Tetrahydroxy-5beta-cholestan-27-oic acid
3alpha,7alpha,15alpha,22S-Tetrahydroxy-5beta-cholestan-26-oic acid
3alpha,7alpha,16alpha,22S-Tetrahydroxy-5beta-cholestan-26-oic acid
3alpha,7alpha,16alpha,24R-Tetrahydroxy-5beta-cholestan-26-oic acid
3alpha,7alpha,12alpha,16alpha-Tetrahydroxy-5beta-cholestan-26-oic acid
24,24-difluoro-1alpha,25-dihydroxy-24a-homovitamin D3
U-73343
U-73343, works as a protonophore, is an inactive analog of U-73122 and can be used as a negative control. U-73343 dose-dependently inhibits acid secretion irrespective of the stimulant. U-73122 is a phospholipase C (PLC) and 5-LO (5-lipoxygenase) inhibitor with an IC50 of 1-2.1 μM for PLC[1][2].
N-[3-(3,5-dimethyl-1-piperidinyl)propyl]-1-[[5-methyl-2-(2-methylphenyl)-4-oxazolyl]methyl]-4-piperidinecarboxamide
(24R,25R)-3alpha,7alpha,12alpha,24-Tetrahydroxy-5beta-cholestan-26-oic acid
(2S,3S,6R)-3-hydroxy-2-methyl-6-((3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)heptanoic acid
(6R)-2-methyl-6-((2R,3S,5S,7R,8R,9S,10S,12S,13R,14S,17R)-2,3,7,12-tetrahydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)heptanoic acid
(24S)-3alpha,7alpha,12alpha,24-tetrahydroxy-5beta-cholestan-26-oic acid
3alpha,7alpha,12alpha,24-tetrahydroxy-5beta-cholestan-26-oic acid with S configuration at C-24.
